歌礼制药-B(01672)：歌礼选定新一代每月一次皮下注射GLP-1R/GIPR/GCGR 三靶点激动剂多肽ASC37进行临床开发

智通财经01-20

智通财经APP讯，歌礼制药-B(01672)发布公告，董事会宣布其已选定新一代每月一次皮下给药的 GLP-1R/GIPR/GCGR三靶点激动剂多肽ASC37注射剂作为临床开发候选药物。歌礼预计将于2026年第二季度向美国食品药品监督管理局(FDA)递交ASC37注射剂治疗肥胖症的新药临床试验申请(IND)。ASC37是一款利用歌礼基于结构的AI辅助药物发现(Artificial ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2604019955?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-01-20 17:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2604019955","market":"sh","top_or_hot":-1,"title":"歌礼制药-B(01672)：歌礼选定新一代每月一次皮下注射GLP-1R/GIPR/GCGR 三靶点激动剂多肽ASC37进行临床开发","media":"智通财经","content":"<div>\n<p>智通财经APP讯，歌礼制药-B(01672)发布公告，董事会宣布其已选定新一代每月一次皮下给药的 GLP-1R/GIPR/GCGR三靶点激动剂多肽ASC37注射剂作为临床开发候选药物。歌礼预计将于2026年第二季度向美国食品药品监督管理局(FDA)递交ASC37注射剂治疗肥胖症的新药临床试验申请(IND)。ASC37是一款利用歌礼基于结构的AI辅助药物发现(Artificial ...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1395129.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>歌礼制药-B(01672)：歌礼选定新一代每月一次皮下注射GLP-1R/GIPR/GCGR 三靶点激动剂多肽ASC37进行临床开发</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n歌礼制药-B(01672)：歌礼选定新一代每月一次皮下注射GLP-1R/GIPR/GCGR 三靶点激动剂多肽ASC37进行临床开发\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-20 17:54 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1395129.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，歌礼制药-B(01672)发布公告，董事会宣布其已选定新一代每月一次皮下给药的 GLP-1R/GIPR/GCGR三靶点激动剂多肽ASC37注射剂作为临床开发候选药物。歌礼预计将于2026年第二季度向美国食品药品监督管理局(FDA)递交ASC37注射剂治疗肥胖症的新药临床试验申请(IND)。ASC37是一款利用歌礼基于结构的AI辅助药物发现(Artificial ...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1395129.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1574","symbol_name":"生物医药B类股","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1395129.html","article_id":"2604019955","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2604019955","pubTimestamp":1768902869,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，歌礼制药-B 发布公告，董事会宣布其已选定新一代每月一次皮下给药的 GLP-1R/GIPR/GCGR三靶点激动剂多肽ASC37注射剂作为临床开发候选药物。体外实验显示，在对GLP-1R、GIPR和GCGR的激动活性方面，ASC37比 retatrutide平均分别强约5倍、4倍和4倍。歌礼计划将GLP-1R/ GIPR/GCGR三靶点激动剂多肽ASC37与其每月一次皮下给药的胰淀素受体激动剂多肽ASC36联用，治疗肥胖症、糖尿病以及其它代谢疾病。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1574":"生物医药B类股","BK1161":"生物科技","BK4590":"PTP","BK4144":"石油与天然气的储存和运输","01477":"欧康维视生物-B","GIPR":"Generation Income Properties Inc.","GLP":"Global Partners Lp","BK1515":"抗疫概念","BK4160":"多样化房地产投资信托v","BK1191":"制药","01672":"歌礼制药-B"},"translate_title":"Ascletis Pharmaceuticals-B (01672): Ascletis selects a new generation of once-monthly subcutaneous injection of GLP-1R/GIPR/GCGR three-target agonist polypeptide ASC37 for clinical development","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GIPR":1.5,"01672":1.5,"01477":1.5,"GLP":1.5},"content_text":"智通财经APP讯，歌礼制药-B(01672)发布公告，董事会宣布其已选定新一代每月一次皮下给药的 GLP-1R/GIPR/GCGR三靶点激动剂多肽ASC37注射剂作为临床开发候选药物。歌礼预计将于2026年第二季度向美国食品药品监督管理局(FDA)递交ASC37注射剂治疗肥胖症的新药临床试验申请(IND)。ASC37是一款利用歌礼基于结构的AI辅助药物发现(Artificial Intelligence-assisted Structure-Based Drug Discovery，AISBDD)、超长效药物开发平台(Ultra-Long-Acting Platform，ULAP)技术自主研发的GLP-1R、GIPR和GCGR三靶点激动剂多肽。体外实验显示，在对GLP-1R、GIPR和GCGR的激动活性方面，ASC37比 retatrutide平均分别强约5倍、4倍和4倍。与每周一次给药的retatrutide相比，经设计优化的ASC37实现了更长的表观半衰期(observed half-life，以血药浓度降至Cmax的50%所需时间计)，从而支持每月一次皮下给药，且注射体积不超过1毫升。这些经设计优化的特性使其在规模化生产中成本更低(scalability advantages in manufacturing)。在非人灵长类动物的头对头研究中，ASC37 专有的皮下储库型制剂(depot formulation)的平均表观半衰期约为17天，是retatrutide在标准液体剂型下的7倍。ASC37注射剂在体外激动活性和表观半衰期方面均优于retatrutide，这些优势表明其有望成为新一代肥胖症疗法。“我们正在推进一款有望实现更强药效、支持每月一次给药的新一代三靶点激动剂ASC37进入临床阶段，”歌礼创始人、董事会主席兼首席执行官吴劲梓博士表示，“我们的这项I期研究预计将于2026年下半年开展，将是我们向改善肥胖人群治疗选择这一全面战略迈进的又一步。”ASC37注射剂正在作为单药及联合疗法进行开发，用于治疗心脏代谢疾病，包括肥胖症、糖尿病和代谢功能障碍相关脂肪性肝炎(MASH)。歌礼计划将GLP-1R/ GIPR/GCGR三靶点激动剂多肽ASC37与其每月一次皮下给药的胰淀素(amylin)受体激动剂多肽ASC36联用，治疗肥胖症、糖尿病以及其它代谢疾病。歌礼的AISBDD与ULAP技术可设计、优化并开发多款每月一次皮下注射超长效多肽，包括ASC35、ASC36和ASC37。基于多肽的特性，本司可利用其专有的 ULAP技术，为皮下储库中的多肽设计多种缓释速率常数(k )，从而在预设的给药间隔内精确释放注射的多肽，降低血药浓度峰谷比并改善临床疗效。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2604019955","isCrawlerRequest":true}